Gemcitabine

Gemcitabine Injection is for intravenous use only., Ovarian Cancer: 1000 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle., Breast Cancer: 1250 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle., Non-Small Cell Lung Cancer: 1000 mg/m 2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle., Pancreatic Cancer: 1000 mg/m 2 over 30 minutes once weekly for the first 7 weeks, then one-week rest, then once weekly for 3 weeks of each 28-day cycle.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Gemcitabine Injection is contraindicated in patients with a known hypersensitivity to gemcitabine. Reactions include anaphylaxis. Patients with a known hypersensitivity to gemcitabine.

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly., Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression., Severe Cutaneous Adverse Reactions (SCARs): Permanently discontinue Gemcitabine Injection if SCARs occur., Pulmonary Toxicity and Respiratory Failure: Discontinue Gemcitabine Injection for unexplained dyspnea or other evidence of severe pulmonary toxicity., Hemolytic Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity, Schedule-Dependent Toxicity, Myelosuppression, Severe Cutaneous Adverse Reactions, Pulmonary Toxicity and Respiratory Failure, Hemolytic Uremic Syndrome, Hepatic Toxicity, Exacerbation of Radiation Therapy Toxicity, Capillary Leak Syndrome, Posterior Reversible Encephalopathy Syndrome The most common adverse…

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

104 products from 50 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 104 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store at 2° to 8°C (36° to 46°F).

Storage information from the U.S. FDA-approved label.